Mar 22 |
Theratechnologies Announces Update on its Preclinical Oncology Research Program
|
Mar 22 |
Theratechnologies Appoints Jordan Zwick to its Board of Directors
|
Mar 21 |
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
|
Feb 29 |
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
|
Feb 27 |
Theratechnologies stock plunges after FDA denies review of Trogarzo sBLA
|
Feb 27 |
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
|
Feb 26 |
Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock
|
Feb 23 |
Theratechnologies Full Year 2023 Earnings: Misses Expectations
|
Feb 21 |
Earnings Scheduled For February 21, 2024
|
Feb 15 |
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
|